artenimol has been researched along with Anemia, Sickle Cell in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 2 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Clapp, S; Freedman, B; Green, CL; Kirui, JK; Korwa, S; Njuguna, FM; O'Meara, WP; Taylor, SM; Wu, A | 1 |
| Akun, P; Galileya, LT; Idro, R; Kalibbala, D; Nambatya, W; Nkosi-Gondwe, T; Opoka, R; Phiri, K; Robberstad, B; Rujumba, J; Ssenkusu, J; TerKuile, F | 1 |
2 trial(s) available for artenimol and Anemia, Sickle Cell
| Article | Year |
|---|---|
Monthly sulfadoxine/pyrimethamine-amodiaquine or dihydroartemisinin-piperaquine as malaria chemoprevention in young Kenyan children with sickle cell anemia: A randomized controlled trial.
Topics: Amodiaquine; Anemia, Sickle Cell; Antimalarials; Artemisinins; Chemoprevention; Child; Child, Preschool; Drug Combinations; Female; Humans; Hydroxyurea; Infant; Kenya; Malaria; Malaria, Falciparum; Male; Proguanil; Pyrimethamine; Sulfadoxine | 2022 |
Dihydroartemisinin-piperaquine or sulphadoxine-pyrimethamine for the chemoprevention of malaria in children with sickle cell anaemia in eastern and southern Africa (CHEMCHA): a protocol for a multi-centre, two-arm, double-blind, randomised, placebo-contro
Topics: Africa, Southern; Anemia, Sickle Cell; Antimalarials; Chemoprevention; Child; Drug Combinations; Humans; Malaria; Multicenter Studies as Topic; Quinolines; Randomized Controlled Trials as Topic | 2023 |